| (USD) | Jun 2026 | Y/Y change |
|---|---|---|
| Revenue | 4.86B | — |
| Operating expense | — | — |
| Net income | 218.00M | — |
| Net profit margin | — | — |
| Earnings per share | — | — |
| EBITDA | — | — |
| Effective tax rate | — | — |
Over the past year, FMS returned -4.7% with dividends reinvested.
| Period | Total return |
|---|---|
| YTD | +2.4% |
| 1 year | -4.7% |
| 5 years | -29.6% |
| 10 years | -33.7% |
| All-time high | $57.51 (Jan 2018) |
Returns are total returns and include reinvested dividends. The all-time high is the highest monthly closing price on record.
See what $1,000 in FMS would be worth today ›Yes. Fresenius Medical Care AG paid 1 dividend over the past 12 months. The most recent was $0.87 per share on May 22, 2026. The dividend yield is 3.72%.
Fresenius Medical Care AG stock trades on NYSE under the ticker symbol FMS.
Fresenius Medical Care AG is part of the Healthcare sector.
Fresenius Medical Care AG has a market cap of 12.48B USD, based on the latest quote.
Fresenius Medical Care AG is expected to report earnings around Nov 3, 2026. That date is an estimate and has not been confirmed by the company.
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company operates through Care Delivery and Care Enablement segments. It also develops, manufactures, and distributes various health care products, including hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular specialty, ambulatory surgery center, physician nephrology practice management, pharmacy and other services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics, as well as through local sales forces, independent distributors, dealers, and sales agents. The company was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
